Workstation developer Silicon Graphics hit the financial marketswith a one-two punch of bad news late last month. The MountainView, CA, company initiated a replacement program to correct problemsin a high-end computer chip and warned that it expects
Workstation developer Silicon Graphics hit the financial marketswith a one-two punch of bad news late last month. The MountainView, CA, company initiated a replacement program to correct problemsin a high-end computer chip and warned that it expects revenuesto be only slightly higher for its first quarter (end-September).
Silicon Graphics chairman and CEO Edward McCracken said thecompany's sluggish sales were due in part to market anticipationof its new O2 workstation, which was introduced on Monday. McCrackensaid the O2 debut was one of SGI's most important new introductionsin several years.
In addition, SGI last month began a replacement program forcustomers who bought workstations shipped between March and Julywith the MIPS R10000 microprocessor. Systems with the affectedmicroprocessors may shut down, the company said. The R10000 chipis a 64-bit microprocessor that was debuted earlier this year(SCAN 1/31/96). Shipments since Aug. 1 are free of the defect.
SGI expected to post revenues only slightly higher than the$758 million recorded last year (including sales of Cray Research,which has SGI acquired), McCracken said. The company said itsnet income will be below market expectations.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.